Stryker Corporation (SYK) Stock Price: $310.58+2.64 (+0.86%)
At close: Jun 16, 2026, 4:00 PM ET
The closing share price for Stryker Corporation (SYK) stock was $310.58 for Tuesday, June 16, 2026, up 0.86% on the day.
Longer view (total return, dividends reinvested): past 12 months -16.9% · 3-year avg +2.8%/yr · 5-year avg +5.0%/yr
SYK Price Chart
SYK Key Metrics
See All MetricsLAST CLOSE PRICE
$310.58
52-WEEK RANGE
$281.00 - $404.87
BETA
0.79
% FROM 52W HIGH
-23.29%
MARKET CAP
$119.06B
DIVIDEND YIELD
1.11%
PE RATIO
trailing TTM
35.95
PE RATIO (FWD)
next-FY estimate
18.56
P/B RATIO
5.22
DEBT / EQUITY
0.73
REVENUE TTM
$25.27B
NET INCOME TTM
$3.34B
NET PROFIT MARGIN TTM
13.21%
TTM TOTAL RETURN
-16.86%
3Y TOTAL RETURN
+2.79%
5Y TOTAL RETURN
+4.98%
SYK Earnings Preview
Next Earnings Date
Jul 30, 2026
43 days away
EPS Estimate
3.49
Revenue Est.
$6.58B
Last Quarter Results
EPS
$2.60
vs Estimate
$2.98
Revenue
$6.02B
vs Estimate
$6.34B
SYK Analyst Ratings
Consensus Rating
Based on 25 analysts
Average Price Target
$386.80
+24.5% upside
Low
$315.00
Current
$310.58
High
$465.00
SYK Analyst Estimates
Earnings Per Share (EPS) Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | $3.24 | $3.30 | $3.38 | 10 |
| Q2 2027 | $3.83 | $3.90 | $3.99 | 7 |
| Q3 2027 | $3.99 | $4.07 | $4.16 | 7 |
| Q4 2027 | $5.35 | $5.45 | $5.58 | 14 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $15.51 | $16.73 | $17.06 | 16 |
| FY 2028 | $17.35 | $18.66 | $20.34 | 7 |
Revenue Estimates
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Q1 2027 | $6.63B | $6.72B | $6.85B | 7 |
| Q2 2027 | $7.01B | $7.12B | $7.25B | 7 |
| Q3 2027 | $7.13B | $7.23B | $7.37B | 7 |
| Q4 2027 | $8.44B | $8.56B | $8.72B | 7 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2027 | $28.96B | $29.60B | $29.87B | 20 |
| FY 2028 | $31.99B | $32.00B | $32.01B | 20 |
Source: FMP Analyst Consensus Estimates. Forward P/E uses the next-fiscal-year consensus EPS estimate (the same value shown in the Key Metrics strip).
Related Stocks
HealthcareSYK Competitors' Key Metrics
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1SYK | $119.06B | $310.58 | +0.86% | -16.86% | +4.98% | +11.71% | — |
| 2BMY | $114.38B | $56.24 | -1.56% | +20.81% | +0.46% | +1.00% | vs SYK |
| 3VRTX | $113.82B | $450.46 | +1.24% | -0.87% | +18.98% | +17.33% | vs SYK |
| 4CVS | $127.54B | $100.68 | -1.26% | +53.06% | +6.84% | +3.58% | vs SYK |
| 5DHR | $128.72B | $181.10 | +0.56% | -8.95% | -3.02% | +11.12% | vs SYK |
| 6MDT | $104.05B | $80.38 | +0.22% | -4.87% | -5.46% | +2.22% | vs SYK |
SYK Charts
Valuation Charts
Performance Charts
CAGR Charts
Financial Statement Charts
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- Capital Expenditure
- Acquisitions
- Share Buybacks
- Stock-Based Compensation
- Total Assets
- Total Equity
- Cash & Equivalents
- Accounts Receivable
- Inventory
- PP&E
- Goodwill
- Accounts Payable
- Retained Earnings
- Total Debt
- Long-Term Debt
- Short-Term Debt
About Stryker Corporation
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Kevin A. Lobo